Core Scientific, Inc. Common Stock (CORZ)
Official siteTECHNOLOGY • SOFTWARE - INFRASTRUCTURE • NASDAQ
Market Cap: $4.68B
Last updated: Nov 17, 2026 at 11:05 AM ET
Core Scientific, Inc. Common Stock (CORZ) Earnings: Report Dates and Results
Core Scientific, Inc. Common Stock (CORZ) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Core Scientific, Inc. Common Stock reported EPS of $0.47. It beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CORZ has an expected report date of Mar 1, 2027.
CORZ Earnings Call
The latest CORZ earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 13 quarters below that had an estimate, CORZ beat 3 and missed 10. Revenue for the quarter ended Sep 30, 2026 was $232.87M, up 187.1% from $81.10M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.47 | -$0.01 | -$0.05 - $0.06 | N/A | N/A | N/A | 4 | 0 up, 0 down | Nov 5, 2026 | $232.87M |
| Jun 30, 2026 | $0.18 | -$0.02 | -$0.10 - -$0.02 | +1000.00% | Beat | N/A | 2 | 0 up, 2 down | Jul 28, 2026 | $164.20M |
| Mar 31, 2026 | -$0.11 | -$0.05 | -$0.07 - -$0.03 | -120.00% | Miss | N/A | 2 | 0 up, 0 down | May 6, 2026 | $115.24M |
| Dec 31, 2025 | -$0.18 | -$0.12 | -$0.12 - -$0.12 | -53.33% | Miss | N/A | 1 | 0 up, 0 down | Mar 2, 2026 | $79.76M |
| Sep 30, 2025 | -$0.20 | $0.07 | $0.07 - $0.07 | -385.71% | Miss | N/A | 1 | 0 up, 1 down | Oct 24, 2025 | $81.10M |
| Jun 30, 2025 | -$0.04 | $0.01 | $0.01 - $0.01 | -500.00% | Miss | N/A | 1 | N/A | Aug 8, 2025 | $78.63M |
| Mar 31, 2025 | -$0.13 | $0.02 | $0.02 - $0.02 | -750.00% | Miss | -181.3% | 1 | 0 up, 1 down | May 7, 2025 | $79.53M |
| Dec 31, 2024 | -$0.13 | $0.05 | $0.05 - $0.05 | -351.40% | Miss | N/A | 1 | 0 up, 0 down | Feb 26, 2025 | $94.92M |
| Sep 30, 2024 | -$0.16 | -$0.04 | N/A | -300.00% | Miss | N/A | 5 | 1 up, 1 down | Nov 6, 2024 | $95.35M |
| Jun 30, 2024 | -$0.04 | $0.12 | N/A | -133.33% | Miss | N/A | 2 | 0 up, 0 down | Aug 7, 2024 | $141.10M |
| Mar 31, 2024 | $0.16 | $0.14 | $0.05 - $0.21 | +14.29% | Beat | N/A | 2 | 0 up, 0 down | May 8, 2024 | $179.29M |
| Dec 31, 2023 | -$0.51 | $0.07 | N/A | -881.85% | Miss | N/A | N/A | N/A | Mar 12, 2024 | $141.93M |
| Sep 30, 2023 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 4, 2023 | $112.90M |
| Sep 30, 2022 | -$1.23 | -$0.17 | N/A | -623.53% | Miss | N/A | N/A | N/A | Nov 28, 2022 | $162.57M |
| Jun 30, 2022 | -$2.65 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2022 | $163.97M |
| Mar 31, 2022 | -$1.52 | $0.16 | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2022 | $192.52M |
| Dec 31, 2021 | $0.41 | $0.33 | N/A | +24.24% | Beat | N/A | N/A | N/A | Mar 29, 2022 | $301.80M |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was $0.36, a profit after a loss of $0.50 per share the year before. It was -$4.99 for the year ended Sep 30, 2022, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | $0.36 | N/A |
| Sep 30, 2025 | -$0.50 | N/A |
| Sep 30, 2024 | -$0.55 | N/A |
| Sep 30, 2023 | -$0.11 | N/A |
| Sep 30, 2022 | -$4.99 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,600 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,583 | 17 | |
| 2026Q1 | Mar 31, 2026 | 5,455 | 15 | |
| 2025Q4 | Dec 31, 2025 | 8,520 | 14 | |
| 2025Q1 | Mar 31, 2025 | 7,530 | 14 | |
| 2024Q4 | Dec 31, 2024 | 7,021 | 17 | |
| 2024Q3 | Sep 30, 2024 | 7,077 | 15 | |
| 2024Q2 | Jun 30, 2024 | 8,439 | 13 |
2026Q3 Earnings Call
Opening remarks
Jon Charbonneau Senior Vice President, Investor Relations Good morning, and welcome to Core Scientific's Third Quarter 2026 Earnings Call. Before we begin, statements made on this call other than historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on our current expectations. Words such as anticipates, estimates, expects, intends, and believes, and similar expressions identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ substantially. For more information, please review the risk factors discussed in the company's reports on Forms 10-Q and 8-K filed today with the SEC, along with the press release and slide presentation included in those filings. Our forward-looking statements speak only as of today. We undertake no obligation to update them to reflect subsequent events or circumstances. Today's presentation is available on our website, investors.corescientific.com. The information on this call is accurate only as of November 5, 2026. Joining me today are Core Scientific's Chief Executive Officer, Adam Sullivan, and Chief Financial Officer, Jim Nygaard. We will hold a question-and-answer session after management's remarks. Adam, over to you.
Adam Sullivan CEO Thanks, Jon, and good morning, everyone. Thank you for joining our Q3 2026 earnings call. Beginning approximately two years ago, we announced a series of colocation agreements with CoreWeave, providing for the development at CoreWeave's expense of 590 MW. While many questioned the strength of this arrangement and its potential to support our future growth, we executed. Today, we have built five data center campuses, and we are billing our customer for a total of 485 MW. The remaining 100 MW is currently in commissioning, and we will begin recognizing additional revenue over the course of the next few months. In addition, these contracts enabled us to raise over $3 billion to fund our next phase of growth and have established a reputation for delivery that helped us win our latest customer contract. At the same time, uncertainty around new data center development in Texas, Georgia, and elsewhere makes our completed operating sites already serving customers and our sites in advanced development with secured power and near-term capacity even more valuable. Our execution has delivered tangible results. GAAP colocation revenue increased nearly 60% sequentially, while Adjusted EBITDA reached over $130 million, up from $41 million in the second quarter. We expect further growth as the remaining CoreWeave capacity comes online in the coming months. As we approach completion of that build-out, we are also advancing the initial 530 MW contracted by AMD. With over 1.1 GW contracted between CoreWeave and AMD and 1.9 GW under reservation with AMD, we have tremendous confidence in our ability to scale.
Frequently Asked Questions About CORZ
When is Core Scientific, Inc. Common Stock's next earnings date?
Core Scientific, Inc. Common Stock's next earnings report is expected for Mar 1, 2027.
What EPS do analysts expect from CORZ next quarter?
The consensus EPS estimate for Core Scientific, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.03 from 19 analysts, with estimates from -$0.42 to $0.23.
How often does CORZ beat earnings estimates?
Core Scientific, Inc. Common Stock beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate, with an average surprise of -182.56%.
CORZ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors